Skip to main
EKSO
EKSO logo

EKSO Stock Forecast & Price Target

EKSO Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ekso Bionics Holdings Inc. demonstrates promising growth potential, highlighted by a projected revenue of $23 million for 2025, anchored in both its legacy enterprise business and the Indego Personal segment. Recent quarterly performance reflects a substantial 21%-24% quarter-over-quarter growth, suggesting a recovery and increased market engagement driven by a higher placement of EksoNR devices. The strategic partnership aimed at expanding the Indego market, combined with anticipated improvements in reimbursement processes, positions Ekso favorably for sustainable long-term revenue growth.

Bears say

Ekso Bionics Holdings Inc experienced a total revenue decline of 2% in 2024, totaling $17.9 million compared to $18.3 million in 2023, primarily due to decreased enterprise sales linked to irregularities in procurement cycles among integrated delivery networks. While there was notable revenue growth in Europe, particularly in France, it could not sufficiently counterbalance the overall revenue drop. Additionally, the significant loss on the revaluation of warrant liabilities raises concerns about the company's financial stability and future earnings potential, further contributing to a negative outlook.

EKSO has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ekso Bionics Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ekso Bionics Hlds (EKSO) Forecast

Analysts have given EKSO a Strong Buy based on their latest research and market trends.

According to 5 analysts, EKSO has a Strong Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ekso Bionics Hlds (EKSO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.